Edesa Biotech, Inc. (EDSA) Revenue History
Annual and quarterly revenue from 2009 to present
EDSA Revenue Over Time (2009–2025)
EDSA Revenue Growth History
4 of 11 years with positive growth- FY2009 revenue growth
- N/A
- FY2010 revenue growth
- N/A
- FY2011 revenue growth
- -18.4%
- FY2012 revenue growth
- -59.0%
- FY2013 revenue growth
- +90.7%
- FY2014 revenue growth
- -31.8%
- FY2015 revenue growth
- +103.9%
- FY2016 revenue growth
- +67.6%
- FY2017 revenue growth
- -82.0%
- FY2018 revenue growth
- -7.2%
- FY2019 revenue growth
- +93.9%
- FY2020 revenue growth
- -20.0%
- FY2021 revenue growth
- -100.0%
- FY2022 revenue growth
- N/A
- FY2023 revenue growth
- N/A
- FY2024 revenue growth
- N/A
- FY2025 revenue growth
- N/A
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $0 | — |
| Q1 2026 | $0 | — |
| Q4 2025 | $0 | — |
| Q3 2025 | $0 | — |
| Q2 2025 | $0 | — |
| Q1 2025 | $0 | — |
| Q4 2024 | $0 | +100.0% |
| Q3 2024 | $0 | — |
Multi-year avg. share of annual revenue by fiscal quarter
Revenue Breakdown (FY 2018)
EDSA's revenue distribution by segment and geography for fiscal year 2018
By Product/Segment
EDSA Revenue Analysis (2009–2025)
Current Revenue & Growth
As of June 12, 2026, Edesa Biotech, Inc. (EDSA) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q2 2026) recorded $0 in revenue
Historical Growth Trajectory
EDSA's historical revenue data shows various trends over time. Edesa Biotech, Inc.'s highest annual revenue of $1.3 million was recorded in 2016.
Revenue by Segment
EDSA's revenue is primarily driven by Product (100%). With over half of revenue concentrated in Product, the company has a focused business model while developing other growth vectors.
Peer Comparison
Compared to Healthcare sector peers — including ADMA (+11.0% YoY), NUVB (+1205.5% YoY), and HALO (+39.1% YoY). Compare EDSA vs ADMA →
EDSA Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
 EDSACurrent | $0 | - | - | - | |
 ADMA | $510M | +11.0% | +64.6% | 37.5% | |
 NUVB | $63M | +1205.5% | - | -338.7% | |
 HALO | $1.4B | +39.1% | +39.2% | 58.4% |
EDSA Historical Revenue Data (2009–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | - | $-119,273 | - | $-7,911,566 | - |
| 2024 | $0 | - | $-186,049 | - | $-7,014,744 | - |
| 2023 | $0 | - | $-183,471 | - | $-9,222,758 | - |
| 2022 | $0 | - | $-118,188 | - | $-18,370,790 | - |
| 2021 | $0 | -100.0% | $-118,788 | - | $-23,681,332 | - |
| 2020 | $329K | -20.0% | $311K | 94.6% | $-6,400,842 | -1946.7% |
| 2019 | $411K | +93.9% | $310K | 75.3% | $-2,832,138 | -689.3% |
| 2018 | $212K | -7.2% | $-233,471 | -110.2% | $-5,078,250 | -2397.1% |
| 2017 | $228K | -82.0% | $-306,166 | -134.1% | $-5,224,546 | -2288.6% |
| 2016 | $1.3M | +67.6% | $144K | 11.3% | $-4,908,356 | -386.0% |
| 2015 | $759K | +103.9% | $-81,558 | -10.7% | $-4,338,592 | -571.9% |
| 2014 | $372K | -31.8% | $-388,127 | -104.3% | $-5,718,516 | -1536.7% |
| 2013 | $545K | +90.7% | $-31,059 | -5.7% | $-3,678,459 | -674.4% |
| 2012 | $286K | -59.0% | $-150,347 | -52.6% | $-6,522,680 | -2280.2% |
| 2011 | $697K | -18.4% | $-311,896 | -44.7% | $-7,099,953 | -1018.4% |
What if you invested $1,000 in EDSA back in 2009?
Total return with dividends reinvested · 17+ years of data
Calculate ReturnsHow much would $100/month in EDSA be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs EDSA Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationEDSA vs LLY — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Eli Lilly and Company.
Compare NowEDSA — Frequently Asked Questions
Quick answers to the most common questions about buying EDSA stock.
Is EDSA's revenue growth accelerating or slowing?
EDSA TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is EDSA's revenue history from 2009 to 2026?
Edesa Biotech, Inc. (EDSA) revenue history spans 2009 to 2026. TTM revenue as of 2026 is $0.00, growing at N/A YoY. The 5-year CAGR is N/A. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is EDSA's long-term revenue growth rate (CAGR)?
Edesa Biotech, Inc.'s 5-year revenue CAGR of N/A reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of N/A is in line with this long-term average. CAGR is the most reliable measure of sustained revenue momentum for EDSA.
Why does EDSA's quarterly revenue fluctuate?
EDSA quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Edesa Biotech, Inc.'s revenue data from 2009 to 2026 shows full historical quarterly detail on this page.
How is EDSA's revenue distributed by segment?
EDSA reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does EDSA's revenue compare to industry peers?
Edesa Biotech, Inc. (EDSA) with TTM revenue of $0.00 and N/A YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.